

BIOMARKERcenter

THE SINGLE, COMPREHENSIVE RESOURCE ON BIOMARKERS
AT ALL STAGES OF DEVELOPMENT



WHAT YOU CAN LEARN

- Which biomarkers are associated with a disease
- How trustworthy each biomarker is
- Whether modifying the activity of a target affects a biomarker
- How safe a drug is
- Optimum doses
- Which biomarkers are appropriate for clinical trials

WHO CAN BENEFIT

- Discovery scientists
- Clinical researchers
- Toxicologists
- Pharmacologists
- Physicians
- Business development and licensing
- Translational medicine scientists
- Bioinformaticians

THE NEW STANDARD IN BIOMARKER RESEARCH

BIOMARKERcenter provides a unique biomarker knowledge store that aims to connect experimental research, drug R&D and clinical studies for pivotal insights and decision making.

A single, comprehensive resource on the biomarkers that are actively being researched or used in all major therapeutic areas, it is the first biomarker database to provide standardized terminology, and to classify biomarkers reliably into life cycle phases and disciplines.

BIOMARKERcenter is reliable in content, rich in analysis, and backed up by rigorous editorial standards and the best possible customer service. It can show you exactly how much trust you can put in the biomarker data you rely on to support your stage gate decisions and plan and execute your clinical trials.

It is available as a subscription option to users of *Prous Science Integrity*®. The data is also available as an XML feed for your in-house bioinformatics solutions.

RELIABLE KNOWLEDGE, PLACED IN CONTEXT AND ASSESSED AT A GLANCE

BIOMARKERcenter covers the biomarkers identified in literature, patents, conferences, medical meetings and other sources for all the key therapy areas: oncology, cardiovascular, metabolism, respiratory, autoimmunology and neurology. For each therapy area, it includes not only biomarkers with established commercial presence but also high potential biomarkers as identified by industry and academia experts.

Each record is manually curated and includes the biomarker's name, classification, biological entities/processes involved, associated drugs, roles or utilities, measurement techniques, development status of diagnostic kits and validation status.

Uniquely, *BIOMARKERcenter* places this wealth of knowledge in context, including related literature, patents, genomics/targets, drugs and biologics, companies or research institutions, toxicology and clinical studies, enabling you to assess the relative importance of each biomarker. Each record is enriched still further with links to all supporting source documents, throughout the history of the biomarker.

BIOMARKERcenter monitors the lifecycle status of the biomarker from discovery to outcome—a pipeline approach that answers at a glance the question of trustworthiness, while providing references for the basis of the categorization.

SUPPORTING BIOMARKER ACCEPTANCE AND PHARMACEUTICAL INNOVATION

BIOMARKERcenter is compiled and curated by the experts at Thomson Reuters, a world authority on the pharmaceutical industry, with extensive participation by key opinion leaders and stakeholders in research, academia and regulatory bodies.

Dynamic, up-to-date, and continually enlarged, it puts at your disposal the most complete, reliable and high quality biomarker information available to the global pharmaceutical community.

By helping you to explore hypotheses and discover data from many different angles, *BIOMARKERcenter* can help you to improve cost efficiency, predict and minimize risk, avoid late stage attrition and make better, more informed decisions.



DISCOVERY BIOLOGISTS

BIOMARKERcenter can help you to learn the biology of the disease you're working on, and to understand the current state of the art regarding biomarkers in your therapy area. You can choose the biomarker that will give early indications on whether modifying a potential new target will have a positive outcome on the disease process.

PRECLINICAL SCIENTISTS

BIOMARKERcenter can help you to find the biomarkers that show the effects of your compound on the disease state. By returning all the biomarkers reported for the disease in question, you can select those which are suitable, saving time in new biomarker research.

CLINICAL TRIALS MANAGERS

BIOMARKERcenter can help you to find the population that will respond best to the particular treatment. Knowing which biomarkers to use can improve the design and efficiency of your studies, and improve your probability of success.

Scientific Head Offices

Americas

Philadelphia +1 800 336 4474
+1 215 386 0100
San Diego +1 858 273 8616

Europe, Middle East and Africa

Barcelona +34 93 459 2220
London +44 20 7433 4000

Asia Pacific

Singapore +65 6411 6888
Tokyo +81 3 5218 6500

For a complete office list visit:

scientific.thomsonreuters.com/contact

GET A QUOTATION

Contact us today to request a no obligation quotation or visit scientific.thomsonreuters.com

